RET and nonpapillary renal cell carcinoma: The combination of belzutifan with TKIs such as cabozantinib (against VEGF receptor (VEGFR), c-MET, AXL, and RET) and lenvatinib (VEGFR1-3, c-Kit, fibroblast growth factor receptors (FGFRs)1-4, platelet-derived growth factor receptors (PDGRs)-α, and RET) has shown promising efficacy in clinical trials for patients with advanced ccRCC.